Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study-Reference-Cited by-同舟云学术

Efficacy and safety of interferon-alpha 1b combined with PD-1 monoclonal antibody in patients with unresectable stage IV melanoma: a retrospective study

Published:2023-01-30 Issue:9 Volume:149 Page:6263-6269
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Zhu Guannan,Shi Qiong,Zhao Bolun,Liu Yu,Feng Ting,Li Chunying,Gao Tianwen

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-04596-3.pdf

Reference18 articles.

1. Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM (2018) Phase Ib/II study of pembrolizumab and pegylated-interferon Alfa-2b in advanced melanoma. J Clin Oncol. https://doi.org/10.1200/JCO.18.00632

2. Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U, Hauschild A (2008) Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. [Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial]. Ann Oncol 19(6):1195–1201. https://doi.org/10.1093/annonc/mdn001

3. Hu T, Sun W, Xu Y, Qu X, Jin Y, Luo Z, Chen Y (2021) Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China. Ann Transl Med 9(21):1625. https://doi.org/10.21037/atm-21-5738

4. Ives NJ, Suciu S, Eggermont A, Kirkwood J, Lorigan P, Markovic SN, Garbe C, Wheatley K (2017) Adjuvant interferon-alpha for the treatment of high-risk melanoma: an individual patient data meta-analysis. [Journal Article; Meta-Analysis; Review; Research Support, Non-U.S. Gov’t]. Eur J Cancer 82:171–183. https://doi.org/10.1016/j.ejca.2017.06.006

5. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. [Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov’t, P.H.S.]. J Clin Oncol 18(12):2444–2458. https://doi.org/10.1200/JCO.2000.18.12.2444

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of PD‐1 monoclonal antibody combined with interferon‐alpha 1b and anlotinib hydrochloride as the second‐line therapy in patients with unresectable advanced melanoma: A retrospective study;Cancer Medicine;2024-08

2. Real-world clinical outcome and safety of adjuvant human Interferon-alpha1b in resected stage IIIB or IIIC melanoma: results of a retrospective study;Holistic Integrative Oncology;2024-05-20

3. Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers;Cancer Drug Resistance;2024-05-13

4. Efficacy and safety of PD‑1 monoclonal antibody combined with interferon‑alpha 1b and anlotinib hydrochloride as the second-line therapy in patients with unresectable advanced melanoma: a retrospective study;2024-03-15